KINTAI Biotech Compares Cytisine and Varenicline for Smoking Cessation

KINTAI Biotech Inc. has issued a comparative analysis of cytisine and varenicline, two compounds utilized in smoking cessation treatments.

The company states that cytisine, extracted from the Sophora alopecuroides plant, is a naturally derived alkaloid with a mechanism of action similar to synthetic varenicline. Both substances function as partial agonists on nicotinic receptors, alleviating withdrawal symptoms and blocking nicotine binding.

Cytisine demonstrates an onset of action within approximately 30 minutes and has a half-life of 4–8 hours, necessitating divided daily doses. Varenicline, conversely, possesses a longer half-life of around 24 hours, allowing for one to two daily administrations. While varenicline exhibits slightly higher receptor affinity, KINTAI Biotech highlights its significantly greater cost.

The company positions cytisine as a preferable ingredient for manufacturers due to its natural origin and cost-effectiveness. The analysis favors cytisine, although specific clinical data or market trend details are not extensively elaborated upon. KINTAI Biotech is a supplier of botanical extracts, marketing high-purity cytisine powder.